Giustino Parruti Giuseppe Marani Toro
10.1186/1471-2334-5-80
BMC Infect Dis
2005 Oct 3;5:80.
CC BY
https://pubmed.ncbi.nlm.nih.gov/16202141/
Anti-HIV Agents / administration & dosage Anti-HIV Agents / adverse effects HIV Infections / drug therapy HIV-Associated Lipodystrophy Syndrome / chemically induced HIV-Associated Lipodystrophy Syndrome / pathology
Anti-HIV Agents / administration & dosage Anti-HIV Agents / adverse effects HIV Infections / drug therapy HIV-Associated Lipodystrophy Syndrome / chemically induced HIV-Associated Lipodystrophy Syndrome / pathology Case Reports Adult Antiretroviral Therapy, Highly Active / adverse effects Female HIV Infections / complications HIV-Associated Lipodystrophy Syndrome / complications HIV-Associated Lipodystrophy Syndrome / physiopathology Humans Time Factors Anti-HIV Agents
PMC1261268
16202141
Persistence of lipoatrophy after a four-year long interruption of antiretroviral therapy for HIV1 infection: case report
2005